In the U.S., 168 healthcare organizations have received accreditation for immune effector cell therapy from the Foundation for the Accreditation of Cellular Therapy. An additional seven received ...

KANSAS CITY, Mo. — Children’s Mercy is expanding its cell and gene therapy program with the help of artificial intelligence (AI). Children’s Mercy said it will be collaborating with Basepath Health, ...

Scientists have developed a way to turn the body's own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions. Current ...

Mesa is seeking a nonprofit to take over its transitional housing program for homeless families and women. Mesa's City Council halted plans to move the program into the city-owned Sunaire Hotel due to ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company ...

Inmates at Central New Mexico Corrections Facility are training shelter dogs, gaining job skills and empathy as the state works to reduce recidivism LOS LUNAS — Justin Stone was never one for dogs, ...

The International Society for Stem Cell Research (ISSCR) today announced the launch of Stem Cell Medicine: Parkinson's Disease, a new continuing education course designed to equip clinicians with an ...

The Knicks load management plan with Mitchell Robinson can be frustrating at times, but it’s hard to argue that it hasn’t worked. Robinson has played 44 games this year, already more than either of ...

The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly is getting a contender through the acquisition of startup Orna Therapeutics for up to $2 ...

A new study has uncovered new genetic rules that determine how CD8 “killer” T cells choose between becoming long-lasting, protective immune cells or slipping into exhausted, dysfunctional states.

Industry-leading non-human primate (NHP) data validates CREATE's differentiated receptor design, targeted RNA-LNP platform, and ability to repeat dose Clinical entry planned H2 2026 CAMBRIDGE, Mass., ...